



NDA 50-664/S-026
NDA 50-665/S-026

SUPPLEMENT APPROVALS

Corden Pharma Latina, S.p.A.
c/o: Clinipace Worldwide, Inc.
Attention: Lisa Johnson
Senior Manager, QA and Regulatory Affairs
4840 Pearl East Circle, Suite 201E
Boulder, CO 80301

Dear Ms. Johnson:

Please refer to your Supplemental New Drug Applications (sNDAs) dated October 28, 2016, received October 28, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

- CEFZIL (cefprozil) Tablets, 250 and 500 mg [NDA 50-664]
- CEFZIL (cefprozil) for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL [NDA 50-665]

These “Prior Approval” supplemental new drug applications provide for removal of the indication Secondary Bacterial Infection of Acute Bronchitis (SBIAB) from the **INDICATIONS AND USAGE** section and the **DOSAGE AND ADMINISTRATION** section of the package insert. These revisions, submitted in response to the Agency’s supplemental request letter dated October 3, 2016, are necessary to furnish information needed for the safe use of these drugs, as the Agency no longer grants the indication of SBIAB.

In addition, updates have been made to NDC numbers in the **HOW SUPPLIED** section of the package insert.

APPROVAL & LABELING

We have completed our review of these supplemental applications and they are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at:

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the enclosed labeling with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at:

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
11/22/2016